This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
5 Stocks in the Spotlight on Trump's Coronavirus Vaccine Optimism
by Ritujay Ghosh
Millions are pinning their hopes on a handful of drugmakers, which are into the final phases of their vaccine trial.
Moderna (MRNA) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Moderna (MRNA) reports narrower-than-expected second-quarter loss. Shares decline presumably on absence of any new data on coronavirus vaccine candidate.
The Zacks Analyst Blog Highlights: Eli Lilly, Moderna, Pfizer, Sanofi, GlaxoSmithKline and BioNTech
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Eli Lilly, Moderna, Pfizer, Sanofi, GlaxoSmithKline and BioNTech
Moderna (MRNA) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Moderna (MRNA) delivered earnings and revenue surprises of 13.89% and 110.50%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Drug/Biotech Stock Q2 Earnings on Aug 5: REGN, MRNA & More
by Kinjel Shah
Let us take a look at five drug/biotech companies, REGN, MRNA, SRPT, ACAD and HZNP, which are gearing up for their earnings release.
5 Growth ETFs & Stocks to Ride the Market Rally
by Sweta Killa
Growth investing has taken the lead over value and is likely to stay given a slew of reasons.
Ligand (LGND) Beats on Q2 Earnings & Sales, Raises View
by Zacks Equity Research
Ligand (LGND) reports better-than-expected second-quarter 2020 earnings and revenues. Stock up.
Pharma Stocks in Focus on Late-Stage Coronavirus Vaccine Trials
by Ritujay Ghosh
Hopes of a vaccine have once again started rising with a number of companies now entering the final phase of their trials.
Top ETF Stories of July
by Sanghamitra Saha
Wall Street has been steady in July despite the rise in coronavirus cases due to fiscal and monetary stimulus, coronavirus vaccine hopes, pent-up consumer demand and decent earnings releases.
Vertex (VRTX) Q2 Earnings & Sales Beat, Revenue Guidance Up
by Zacks Equity Research
Vertex (VRTX) raises its revenue guidance on the strong uptake of its newest CF drug, Trikafta. Shares rise in after-hours trading.
Coronavirus Vaccine Efforts Key to Moderna (MRNA) Q2 Earnings
by Zacks Equity Research
Moderna (MRNA) is progressing with coronavirus vaccine development. The company has initiated a late-stage study and investors will likely focus any preliminary data from the study
AstraZeneca (AZN) Q2 Earnings & Sales Beat, Increase Y/Y
by Zacks Equity Research
AstraZeneca (AZN) comes up with better-than expected Q2 results. It maintains its financial outlook for the year. Stock up.
Will Moderna (MRNA) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Moderna (MRNA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Biotech Stock Roundup: Amgen Reports Q2, GILD's CAR T Therapy Gets Approval & More
by Zacks Equity Research
The biotech sector remains in focus with earnings, regulatory and other pipeline updates.
Is Moderna (MRNA) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (MRNA) Outperforming Other Medical Stocks This Year?
Moderna Turns Red Hot: Biotech ETFs to Bet On
by Sweta Killa
Moderna skyrocketed 245% since it announced its COVID-19 vaccine candidate mRNA-1273 on Feb 10. The solid run is likely to continue as most of the analysts are optimistic on the stock.
Moderna (MRNA) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Moderna (MRNA) closed the most recent trading day at $81.49, moving +1.98% from the previous trading session.
Late-Stage Coronavirus Vaccine Trials Begin: Biotech ETFs to Gain
by Sweta Jaiswal, FRM
Two major vaccine developers' entrance into the final stage trials is expected to boost investor optimism.
Coronavirus Vaccine Efforts Key to Novavax (NVAX) Q2 Earnings
by Zacks Equity Research
Novavax (NVAX) is developing a coronavirus vaccine. While increased clinical activity is expected to have increased expenses, pipeline development grants may have offered some respite in Q2 earnings.
Moderna (MRNA) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Investors focus is likely to be on the progress of its pipeline candidates, especially coronavirus vaccine candidate, on the second-quarter earrings call.
Stock Market News for Jul 28, 2020
by Zacks Equity Research
Possibility of a coronavirus rescue program and positive expectations about tech earnings helped benchmarks close higher on Monday.
Coronavirus Vaccine Development Puts These Stocks in Focus
by Ritujay Ghosh
Moderna and Pfizer launches two 30,000-subject trials of COVID-19 vaccines that could clear the way for regulatory approval and widespread use by the end of this year.
COVID-19 Vaccine Push Brings Hope: Stock & ETF Beneficiaries
by Sanghamitra Saha
There are at least a hundred candidates in the COVID-19 vaccine race globally. However, few companies like Moderna, Pfizer and AstraZeneca are showing considerable hope.
New Stimulus, Moderna & Durable Goods Kick Off Monday
by Mark Vickery
We have $1 trillion in stimulus expected from the congressional GOP today and a phase 3 trial beginning for Moderna's (MRNA) COVID-19 vaccine candidate.
Economic Data Deluge
by Zacks Equity Research
Economic Data Deluge